AstraZeneca enters into an agreement with Covis Pharma to sell its rights to Alvesco, Omnaris and Zetonna

CAMBRIDGE, 07-Nov-2018 — /EuropaWire/ — AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines. Covis Pharma currently commercialises Alvesco, Omnaris and Zetonna in the US and will become the owner of the medicines upon closing. The transaction does not include the transfer of any AstraZeneca employees or facilities.
Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, said: “One of our strategic objectives is to divest parts of our portfolio, allowing us to allocate resources to develop innovative new medicines to address unmet patient needs. Covis Pharma has strong capabilities in marketing medicines around the world, and our agreement with them means patients will continue to benefit from Alvesco, Omnaris and Zetonna.”
Michael Porter, Chief Executive Officer, Covis Pharma, said: “This is an exciting milestone for Covis Pharma and aligned with our strategy to build a global respiratory/allergy franchise. When we acquired the US rights for Alvesco, Omnaris and Zetonnain 2017, we recognised the importance of these medicines in the respiratory and allergy therapeutic area and we look forward to extending our reach to meet the needs of patients and physicians around the world.”
Alvesco is an inhaled anti-inflammatory maintenance therapy delivered by a metered-dose inhaler to help control persistent asthma. Omnaris and Zetonna are nasal sprays for the treatment of nasal symptoms associated with seasonal allergic and allergic/non-allergic perennial rhinitis. The active ingredient in all three medicines is ciclesonide, a synthetic corticosteroid that helps relieve inflammation.
Financial Considerations
Covis Pharma will pay AstraZeneca $350 million upon closing, in addition to conditional sales-related payments of up to $21 million over four years from 2019. The agreement is subject to customary closing conditions and is expected to complete by the end of 2018. As AstraZeneca will not maintain a significant ongoing interest in the medicines following completion, the payments will be recognised as Other Operating Income in the Company’s financial statements. Combined 2017 Product Sales of Alvesco, Omnaris and Zetonna, recorded by AstraZeneca, were $106 million. The agreement does not affect the Company’s financial guidance for 2018.
About Covis Pharma
Covis Pharma is headquartered in Zug, Switzerland and is a global speciality pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Additional information is available at www.covispharma.com.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
SOURCE: AstraZeneca PLC
CONTACTS

Media Relations

Karen Birmingham
UK/Global
+44 203 749 5634

Rob Skelding
UK/Global
+44 203 749 5821

Matt Kent
UK/Global
+44 203 749 5906

Gonzalo Viña
UK/Global
+44 203 749 5916

Jennifer Hursit
UK/Global
+44 203 749 5762

Jacob Lund
Sweden
+46 8 553 260 20

Michele Meixell
US
+1 302 885 2677

Investor Relations

Thomas Kudsk Larsen

+44 203 749 5712

Henry Wheeler
Oncology
+44 203 749 5797

Christer Gruvris
Cardiovascular; Metabolism
+44 203 749 5711

Nick Stone
Respiratory; Renal
+44 203 749 5716

Josie Afolabi
Other
+44 203 749 5631

Craig Marks
Finance; Fixed Income
+44 7881 615 764

Jennifer Kretzmann
Retail Investors
+44 203 749 5824

US toll-free

+1 866 381 7277